SEARCH

SEARCH BY CITATION

References

  • Abshire, T.C., Pollock, B.H., Billett, A.L., Bradley, P. & Buchanan, G.R. (2000) Weekly polyethylene glycol conjugated l-asparaginase compared with biweekly dosing produces superior induction remission rates in childhood relapsed acute lymphoblastic leukemia: a Pediatric Oncology Group Study. Blood, 96, 17091715.
  • Ahlke, E., Nowak-Göttl, U., Schulze-Westhoff, P., Werber, G., Börste, H., Würthwein, G., Jürgens, H. & Boos, J. (1997) Dose reduction of asparaginase under pharmacokinetic and pharmacodynamic control during induction therapy in children with acute lymphoblastic leukaemia. British Journal of Haematology, 96, 675681.
  • Albertsen, B.K., Jakobsen, P., Schroder, H., Schmiegelow, K. & Carlsen, N.T. (2001a) Pharmacokinetics of Erwinia asparaginase after intravenous and intramuscular administration. Cancer Chemotherapy and Pharmacology, 48, 7782.
  • Albertsen, B.K., Schroder, H., Jakobsen, P., Müller, H.J., Carlsen, N.T. & Schmiegelow, K. (2001b) Monitoring of Erwinia asparaginase therapy in childhood ALL in the Nordic countries. British Journal of Clinical Pharmacology, 52, 433437.
  • Albertsen, B.K., Schroder, H., Jakobsen, P., Avramis, V.I., Müller, H.J., Schmiegelow, K. & Carlsen, N.T. (2002) Antibody formation during intravenous and intramuscular therapy with Erwinia asparaginase. Medical and Pediatric Oncology, 38, 310316.
  • Appel, I.M., Pinheiro, J.P., Den Boer, M.L., Lanvers, C., Reniers, N.C., Boos, J. & Pieters, R. (2003) Lack of asparagine depletion in the cerebrospinal fluid after one intravenous dose of PEG-asparaginase: a window study at initial diagnosis of childhood ALL. Leukemia, 17, 22542256.
  • Asselin, B.L. (1999) The three asparaginases. Comparative pharmacology and optimal use in childhood leukemia. Advances in Experimental Medicine and Biology, 457, 621629.
  • Asselin, B.L., Whitin, J.C., Coppola, D.J., Rupp, I.P., Sallan, S.E. & Cohen, H.J. (1993) Comparative pharmacokinetic studies of three asparaginase preparations. Journal of Clinical Oncology, 11, 17801786.
  • Avramis, V.I. & Holcenberg, J.S. (2002) PEG-asparaginase and deamination of serum asparagine in children with standard-risk lymphoblastic leukemia (CCG-1962) [author reply]. Blood, 100, 19241925.
  • Avramis, V.I., Sencer, S., Periclou, A.P., Sather, H., Bostrom, B.C., Cohen, L.J., Ettinger, A.G., Ettinger, L.J., Franklin, J., Gaynon, P.S., Hilden, J.M., Lange, B., Majlessipour, F., Mathew, P., Needle, M., Neglia, J., Reaman, G., Holcenberg, J.S. & Stork, L. (2002) A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study. Blood, 99, 19861994. Erratum in: Blood, 2002, 100, 1531.
  • Becker, F.F. & Broome, J.D. (1967) l-asparaginase: inhibition of early mitosis in regenerating rat liver. Science, 156, 16021603.
  • Becker, F.F. & Broome, J.D. (1969) l-asparaginase: inhibition of endogenous RNA polymerase activity in regenerating liver. Archives of Biochemistry and Biophysics, 130, 332336.
  • Berg, S.L., Balis, F.M., McCully, C.L., Godwin, K.S. & Poplack, D.G. (1993) Pharmacokinetics of PEG-l-asparaginase and plasma and cerebrospinal fluid l-asparagine concentrations in the rhesus monkey. Cancer Chemotherapy and Pharmacology, 32, 310314.
  • Billett, A.L., Carls, A., Gelber, R.D. & Sallan, S.E. (1992) Allergic reactions to Erwinia asparaginase in children with acute lymphoblastic leukemia who had previous allergic reactions to Escherichia coli asparaginase. Cancer, 70, 201206.
  • Boos, J., Werber, G., Ahlke, E., Schulze-Westhoff, P., Nowak-Göttl, U., Würthwein, G., Verspohl, E.J., Ritter, J. & Jürgens, H. (1996) Monitoring of asparaginase activity and asparagine levels in children on different asparaginase preparations. European Journal of Cancer, 32A, 15441550.
  • Brueck, M., Koerholz, D., Nuernberger, W., Juergens, H., Goebel, U. & Wahn, V. (1989) Elimination of l-asparaginase in children treated for acute lymphoblastic leukemia. Developmental Pharmacology and Therapeutics, 12, 200204.
  • Cooney, D.A. & Handschumacher, R.E. (1970) l-asparaginase and l-asparagine metabolism. Annual Review of Pharmacology, 10, 421440.
  • Duval, M., Suciu, S., Ferster, A., Rialland, X., Nelken, B., Lutz, P., Benoit, Y., Robert, A., Manel, A.M., Vilmer, E., Otten, J. & Philippe, N. (2002) Comparison of Escherichia coli-asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: results of a randomized European Organisation for Research and Treatment of Cancer-Children's Leukemia Group phase 3 trial. Blood, 99, 27342739.
  • Eden, O.B., Harrison, G., Richards, S., Lilleyman, J.S., Bailey, C.C., Chessells, J.M., Hann, I.M., Hill, F.G. & Gibson, B.E. (2000) Long-term follow-up of the United Kingdom Medical Research Council protocols for childhood acute lymphoblastic leukaemia, 1980–1997. Medical Research Council Childhood Leukaemia Working Party. Leukemia, 14, 23072320.
  • Ertel, I.J., Nesbit, M.E., Hammond, D., Weiner, J. & Sather, H. (1979) Effective dose of l-asparaginase for induction of remission in previously treated children with acute lymphocytic leukemia: a report from Children's Cancer Study Group. Cancer Research, 39, 38933896.
  • Ettinger, L.J., Kurtzberg, J., Voute, P.A., Jürgens, H. & Halpern, S.L. (1995) An open-label, multicenter study of polyethylene glycol-l-asparaginase for the treatment of acute lymphoblastic leukemia. Cancer, 75, 11761181.
  • Evans, W.E., Tsiatis, A., Rivera, G., Murphy, S.B., Dahl, G.V., Denison, M., Crom, W.R., Barker, L.F. & Mauer, A.M. (1982) Anaphylactoid reactions to Escherichia coli and Erwinia asparaginase in children with leukemia and lymphoma. Cancer, 49, 13781383.
  • Gaynon, P.S., Trigg, M.E., Heerema, N.A., Sensel, M.G., Sather, H.N., Hammond, G.D. & Bleyer, W.A. (2000) Children's Cancer Group trials in childhood acute lymphoblastic leukemia: 1983–1995. Leukemia, 14, 22232233.
  • Gentili, D., Conter, V., Rizzari, C., Tschuemperlin, B., Zucchetti, M., Orlandoni, D., D'Incalci, M. & Masera, G. (1996) l-asparagine depletion in plasma and cerebro-spinal fluid of children with acute lymphoblastic leukemia during subsequent exposures to Erwinial-asparaginase. Annals of Oncology, 7, 725730.
  • Gerrits, G.P., Trijbels, F.J., Monnens, L.A., Gabreels, F.J., De Abreu, R.A., Theeuwes, A.G. & van Raay-Selten, B. (1989) Reference values for amino acids in cerebrospinal fluid of children determined using ion-exchange chromatography with fluorimetric detection. Clinica Chimica Acta, 182, 271280.
  • Haley, E.E., Fischer, G.A. & Welch, A.D. (1961) The requirement for l-asparagine of mouse leukemia cells L5178Y in culture. Cancer Research, 21, 532536.
  • Harris, J.M. & Chess, R.B. (2003) Effect of pegylation on pharmaceuticals. Nature Reviews. Drug Discovery, 2, 214221.
  • Ho, D.H., Brown, N.S., Yen, A., Holmes, R., Keating, M., Abuchowski, A., Newman, R.A. & Krakoff, I.H. (1986) Clinical pharmacology of polyethylene glycol-l-asparaginase. Drug Metabolism and Disposition, 14, 349352.
  • Holle, L.M. (1997) Pegaspargase: an alternative? Annals of Pharmacotherapy, 31, 616624.
  • Jaffe, N., Traggis, D., Das, L., Moloney, W.C., Hann, H.W., Kim, B.S. & Nair, R. (1971) l-asparaginase in the treatment of neoplastic diseases in children. Cancer Research, 31, 942949.
  • Kamisaki, Y., Wada, H., Yagura, T., Matsushima, A. & Inada, Y. (1981) Reduction in immunogenicity and clearance rate of Escherichia colil-asparaginase by modification with monomethoxypolyethylene glycol. Journal of Pharmacology and Experimental Therapeutics, 216, 410414.
  • Keating, M.J., Holmes, R., Lerner, S. & Ho, D.H. (1993) l-asparaginase and PEG asparaginase – past, present, and future. Leukemia and Lymphoma, 10(Suppl.), 153157.
  • Killander, D., Dohlwitz, A., Engstedt, L., Franzen, S., Gahrton, G., Gullbring, B., Holm, G., Holmgren, A., Hoglund, S., Killander, A., Lockner, D., Mellstedt, H., Moe, P.J., Palmblad, J., Reizenstein, P., Skarberg, K.O., Swedberg, B., Uden, A.M., Wadman, B., Wide, L. & Ahstrom, L. (1976) Hypersensitive reactions and antibody formation during l-asparaginase treatment of children and adults with acute leukemia. Cancer, 37, 220228.
  • Kurtzberg, J. (1994) A new look at PEG-l-asparaginase and other asparaginases in hematological malignancies. Cancer Investigation, 12(Suppl. 1), 5960.
  • Kurtzberg, J., Asselin, B., Poplack, D., Grebanier, A., Chen, R., Franklin, A., Scudiery, D. & Fisherman, J. (1993) Antibodies to asparaginase alter pharmacokinetics and decrease enzyme activity in patients on asparaginase therapy. Proceedings of the American Association for Cancer Research, 34, 304.
  • Lanvers, C., Vieira Pinheiro, J.P., Hempel, G., Wuerthwein, G. & Boos, J. (2002) Analytical validation of a microplate reader-based method for the therapeutic drug monitoring of l-asparaginase in human serum. Analytical Biochemistry, 309, 117126.
  • Lepage, N., McDonald, N., Dallaire, L. & Lambert, M. (1997) Age-specific distribution of plasma amino acid concentrations in a healthy pediatric population. Clinical Chemistry, 43, 23972402.
  • Mashburn, L.T. & Wriston, J.C. (1964) Tumor inhibitory effect from Escherichia coli. Archives of Biochemistry and Biophysics, 105, 450452.
  • Müller, H.J. & Boos, J. (1998) Use of l-asparaginase in childhood ALL. Critical Reviews in Oncology and Hematology, 28, 97113.
  • Müller, H.J., Loning, L., Horn, A., Schwabe, D., Gunkel, M., Schrappe, M., von Schutz, V., Henze, G., Casimiro da Palma, J., Ritter, J., Pinheiro, J.P., Winkelhorst, M. & Boos, J. (2000) Pegylated asparaginase (Oncaspar) in children with ALL: drug monitoring in reinduction according to the ALL/NHL-BFM 95 protocols. British Journal of Haematology, 110, 379384.
  • Müller, H.J., Beier, R., Loning, L., Blutters-Sawatzki, R., Dorffel, W., Maass, E., Muller-Weihrich, S., Scheel-Walter, H.G., Scherer, F., Stahnke, K., Schrappe, M., Horn, A., Lumkemann, K. & Boos, J. (2001) Pharmacokinetics of native Escherichia coli asparaginase (Asparaginase medac) and hypersensitivity reactions in ALL-BFM 95 reinduction treatment. British Journal of Haematology, 114, 794799.
  • Müller, H.J., Beier, R., Da Palma, J.C., Lanvers, C., Ahlke, E., von Schutz, V., Gunkel, M., Horn, A., Schrappe, M., Henze, G., Kranz, K. & Boos, J. (2002) PEG-asparaginase (Oncaspar) 2500 U/m(2) BSA in reinduction and relapse treatment in the ALL/NHL-BFM protocols. Cancer Chemotherapy and Pharmacology, 49, 149154.
  • Nesbit, M., Chard, R., Evans, A., Karon, M. & Hammond, G.D. (1979) Evaluation of intramuscular versus intravenous administration of l-asparaginase in childhood leukemia. American Journal of Pediatric Hematology and Oncology, 1, 913.
  • Nesbit, M.E., Ertel, I. & Hammond, G.D. (1981) l-asparaginase as a single agent in acute lymphocytic leukemia: survey of studies form Children's Cancer Study Group. Cancer Treatment Reports, 65(Suppl. 4), 101107.
  • Oettgen, H.F., Old, L.J., Boyse, E.A., Campbell, H.A., Philips, F.S., Clarkson, B.D., Tallal, L., Leeper, R.D., Schwartz, M.K. & Kim, J.H. (1967) Inhibition of leukemias in man by l-asparaginase. Cancer Research, 27, 26192631.
  • Ohnuma, T., Holland, J.F., Freeman, A. & Sinks, L.F. (1970) Biochemical and pharmacological studies with asparaginase in man. Cancer Research, 30, 22972305.
  • Ohnuma, T., Holland, J.F. & Meyer, P. (1972) Erwinia carotovora asparaginase in patients with prior anaphylaxis to asparaginase from E. coli. Cancer, 30, 376381.
  • Park, Y.K., Abuchowski, A., Davis, S. & Davis, F. (1981) Pharmacology of Escherichia coli-l-asparaginase polyethylene glycol adduct. Anticancer Research, 1, 373376.
  • Prager, M.D. & Bachynsky, N. (1968) Asparagine synthetase in normal and malignant tissues: correlation with tumor sensitivity to asparaginase. Archives of Biochemistry and Biophysics, 127, 645654.
  • Riccardi, R., Holcenberg, J.S., Glaubiger, D.L., Wood, J.H. & Poplack, D.G. (1981) l-asparaginase pharmacokinetics and asparagine levels in cerebrospinal fluid of rhesus monkeys and humans. Cancer Research, 41(Pt 1), 45544558.
  • Rizzari, C., Zucchetti, M., Conter, V., Diomede, L., Bruno, A., Gavazzi, L., Paganini, M., Sparano, P., Lo Nigro, L., Arico, M., Milani, M. & D'Incalci, M. (2000) l-asparagine depletion and l-asparaginase activity in children with acute lymphoblastic leukemia receiving i.m. or i.v. Erwinia C. or E. colil-asparaginase as first exposure. Annals of Oncology, 11, 189193.
  • Schellekens, H. (2002) Immunogenicity of therapeutic proteins: clinical implications and future prospects. Clinical Therapeutics, 24, 17201740.
  • Schrappe, M., Reiter, A., Zimmermann, M., Harbott, J., Ludwig, W.D., Henze, G., Gadner, H., Odenwald, E. & Riehm, H. (2000) Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Berlin–Frankfurt–Munster. Leukemia, 14, 22052222.
  • Schwartz, M.K., Lash, E.D., Oettgen, H.F. & Tomato, F.A. (1970) l-asparaginase activity in plasma and other biological fluids. Cancer, 25, 244252.
  • Silverman, L.B., Gelber, R.D., Dalten, V.K., Asselin, B.L., Barr, R.D., Clavell, L.A., Hurwitz, C.A., Moghrabi, A., Samson, Y., Schorin, M.A., Arkin, S., Declerck, L., Cohen, H.J. & Sallan, S.E. (2001) Improved outcome for children with acute lymphoblastic leukaemia: results of Dana-Farber Consortium Protocol 91–01. Blood, 97, 12111218.
  • Story, M.D., Voehringer, D.W., Stephens, L.C. & Meyn, R.E. (1993) l-asparaginase kills lymphoma cells by apoptosis. Cancer Chemotherapy and Pharmacology, 32, 129133.
  • Sutow, W.W., Garcia, F., Starling, K.A., Williams, T.E., Lane, D.M. & Gehan, E.A. (1971) l-asparaginase therapy in children with advanced leukemia. The Southwest Cancer Chemotherapy Study Group. Cancer, 28, 819824.
  • Tallal, L., Tan, C., Oettgen, H., Wollner, N., McCarthy, M., Helson, L., Burchenal, J., Karnofsky, D. & Murphy, M.L. (1970) E. colil-asparaginase in the treatment of leukemia and solid tumors in 131 children. Cancer, 25, 306320.
  • Ueno, T., Ohtawa, K., Mitsui, K., Kodera, Y., Hiroto, M., Matsushima, A., Inada, Y. & Nishimura, H. (1997) Cell cycle arrest and apoptosis of leukemia cells induced by l-asparaginase. Leukemia, 11, 18581861.
  • Vieira Pinheiro, J.P., Ahlke, E., Nowak-Göttl, U., Hempel, G., Müller, H.J., Lümkemann, K., Schrappe, M., Rath, B., Fleischhack, G., Mann, G. & Boos, J. (1999) Pharmacokinetic dose adjustment of Erwinia asparaginase in protocol II of the paediatric ALL/NHL-BFM treatment protocols. British Journal of Haematology, 104, 313320.
  • Vieira Pinheiro, J.P., Müller, H.J., Schwabe, D., Gunkel, M., Casimiro da Palma, J., Henze, G., von Schütz, V., Winkelhorst, M., Würthwein, G. & Boos, J. (2001) Drug monitoring of low-dose PEG-asparaginase (Oncaspar) in children with relapsed acute lymphoblastic leukaemia. British Journal of Haematology, 113, 115119.
  • Vieira Pinheiro, J.P., Lanvers, C., Würthwein, G., Beier, R., Casimiro da Palma, J., von Stackelberg, A. & Boos, J. (2002) Drug monitoring of PEG-asparaginase treatment in childhood acute lymphoblastic leukemia and non-Hodgkin's lymphoma. Leukemia and Lymphoma, 43, 19111920.
  • Vilmer, E., Suciu, S., Ferster, A., Bertrand, Y., Cave, H., Thyss, A., Benoit, Y., Dastugue, N., Fournier, M., Souillet, G., Manel, A.M., Robert, A., Nelken, B., Millot, F., Lutz, P., Rialland, X., Mechinaud, F., Boutard, P., Behar, C., Chantraine, J.M., Plouvier, E., Laureys, G., Brock, P., Uyttebroeck, A., Margueritte, G., Plantaz, D., Norton, L., Francotte, N., Gyselinck, J., Waterkeyn, C., Solbu, G., Philippe, N. & Otten, J. (2000) Long-term results of three randomized trials (58831, 58832, 58881) in childhood acute lymphoblastic leukemia: a CLCG-EORTC report. Children Leukemia Cooperative Group. Leukemia, 14, 22572266.
  • Wade, H.E., Elsworth, R., Herbert, E., Keppie, J. & Sargeant, K. (1968) A new l-asparaginase with antitumor activity? Lancet, 2, 776777.
  • Wang, B., Hak, L.J., Relling, M.V., Pui, C.H., Woo, M.H. & Storm, M.C. (2000) ELISA to evaluate plasma anti-asparaginase IgG concentrations in patients with acute lymphoblastic leukemia. Journal of Immunological Methods, 239, 7583.
  • Wang, B., Relling, M.V., Storm, M.C., Woo, M.H., Ribeiro, R., Pui, C.H. & Hak, L.J. (2003) Evaluation of immunologic crossreaction of antiasparaginase antibodies in acute lymphoblastic leukemia (ALL) and lymphoma patients. Leukemia, 17, 15831588.
  • Woo, M.H., Hak, L.J., Storm, M.C., Evans, W.E., Sandlund, J.T., Rivera, G.K., Wang, B., Pui, C.H. & Relling, M.V. (1998) Anti-asparaginase antibodies following E. coli asparaginase therapy in pediatric acute lymphoblastic leukemia. Leukemia, 12, 15271533.
  • Woo, M.H., Hak, L.J., Storm, M.C., Gajjar, A.J., Sandlund, J.T., Harrison, P.L., Wang, B., Pui, C.H. & Relling, M.V. (1999) Cerebrospinal fluid asparagine concentrations after Escherichia coli asparaginase in children with acute lymphoblastic leukemia. Journal of Clinical Oncology, 17, 15681573.
  • Wriston, J.C. & Yellin, T.O. (1973) l-asparaginase: a review. Advances in Enzymology and Related Areas of Molecular Biology, 39, 185248.